Table 2.

Detailed characteristics of subjects with pulmonary arterial endothelial cell culture success

No.	Age	Sex	Diagnosis	RAP, mm Hg	mPAP, mm Hg	PCWP, mm Hg	CO, L/min	PVR, Wood units	PAH treatment, time of procedure
1	75	F	PAPVR	12	26	14	9.9	1.2	ERA
2	70	M	Systemic sclerosis	17	47	8	4.7	8.3	None
3	79	F	CPC-PH	13	41	22	3.8	5.0	None
4	78	M	Anti-synthetase syndrome, ILD	14	53	15	3.9	9.7	None
5	37	F	Idiopathic PAH, vasoresponder	7	25	9	7.4	2.2	PDE5i, ERA, CCB
6	69	M	Congenital heart disease	18	48	16	5.1	6.3	PDE5
7*	56	F	Portopulmonary hypertension	4	34	12	12.9	1.7	PDE5i, ERA, PA
8	84	F	Systemic sclerosis, HFpEF	15	60	22	3.3	11.5	None
9	59	F	Systemic sclerosis, exercise PH	10	21	13	7.7	1.0	None
10*	58	M	HIV, COPD	10	29	16	5.0	2.6	ERA
11	44	M	Sarcoid	24	50	6	4.5	9.8	None
12	84	F	Idiopathic PAH	10	43	13	4.5	6.7	None
13	52	F	HIV	14	57	11	4.9	9.4	PDE5i, PA
14	72	M	Unexplained dyspnea	7	20	11	4.1	2.2	None
15	81	F	COPD, HFpEF, OSA	8	35	13	4.3	5.1	None
16	68	F	Sjogren’s syndrome	7	24	9	3.8	3.9	None
17	54	M	ESRD, OSA, ILD	8	46	15	4.8	6.5	None
18	43	F	Idiopathic PAH	4	33	6	5.6	4.8	PDE5i, ERA
19	76	M	COPD	2	38	7	3.9	7.9	None

^*Subject 7 culture success from 1/3 balloons; subject 10 culture success from 1/2 balloons. RAP=right atrial pressure; mPAP=mean pulmonary artery pressure; PCWP=pulmonary capillary wedge pressure; CO=cardiac output; PVR=pulmonary vascular resistance; PAH=pulmonary arterial hypertension; PAPVR=partial anomalous pulmonary venous return; CPC-PH=combined pre- and post-capillary pulmonary hypertension; ILD=interstitial lung disease; HFpEF=heart failure with preserved ejection fraction; HIV=human immunodeficiency virus; COPD=chronic obstructive pulmonary disease; OSA=obstructive sleep apnea; ESRD=end-stage renal disease; PDE5i=phosphodiesterase type 5 inhibitor; ERA=endothelin receptor antagonist; CCB=calcium channel blocker; PA=prostacyclin analogue